Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial

Overview of attention for article published in Arthritis & Rheumatology, March 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter: 15 X users

Readers on

mendeley: 15 Mendeley

So far, Altmetric has seen 20 X posts from 15 X users, with an upper bound of 45,680 followers.

Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial https://t.co/VJmp9CRpB8

RT @BU_BMC_Rheum: Here is the citation https://t.co/TlEvBSJ6x8 https://t.co/nsWxuwW3sU

Here is the citation https://t.co/TlEvBSJ6x8

RT @ACR_Journals: Early view “Notes from the Field” in Arthritis & Rheumatology: Reassessing the Cardiovascular Safety of Febuxostat: Impl…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 16 additional X posts.